Single ascending dose study of AP30663
- Conditions
- Atrial fibrillation
- Registration Number
- NL-OMON29359
- Lead Sponsor
- Acesion Pharma ApSOle Maaløes Vej 3DK-2200 Copenhagen NDenmark
- Brief Summary
To be published
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 48
1. Signed informed consent prior to any study-mandated procedure
2. Healthy male subjects, 18 to 45 years of age, inclusive.
1. Evidence of any active or chronic disease or condition that could interfere with, or for which
the treatment might interfere with, the conduct of the study, or that would pose an
unacceptable risk to the subject in the opinion of the investigator (following a detailed
medical history, physical examination, vital signs (systolic and diastolic blood pressure, pulse
rate, body temperature), 12-lead electrocardiogram (ECG), and clinical laboratory
parameters (haematology, blood chemistry, and urinalysis)). Minor deviations of laboratory
values from the normal range may be accepted, if judged by the Investigator or medically
qualified designee as not clinically significant.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method